BACKGROUND: The American College of Surgery Oncology Group (ACOSOG) trials z4032 and z4033 prospectively characterized lung cancer patients as "high-risk" for surgical intervention, and these results have appeared frequently in the literature. We hypothesized that many patients who meet the objective enrollment criteria for these trials ("high-risk") have similar perioperative outcomes as "normal-risk" patients. METHODS: We reviewed a prospective institutional database and classified patients undergoing resection for clinical stage I lung cancer as "high-risk" and "normal-risk" by ACOSOG major criteria. RESULTS: From 2000 to 2010, 1,066 patients underwent resection for clinical stage I lung cancer. Of these, 194 (18%) met ACOSOG major criteria for risk (preoperative forced expiratory volume in 1 second or diffusion capacity of the lung for carbon monoxide≤50% predicted). "High-risk" patients were older (66.4 vs 64.6 years, p=0.02) but similar to controls in sex, prevalence of hypertension, diabetes, and coronary artery disease. "High-risk" patients were less likely than "normal-risk" patients to undergo a lobectomy (117 of 194 [60%] vs 665 of 872 [76%], p<0.001). "High-risk" and control patients experienced similar morbidity (any complication: 55 of 194 [28%] vs 230 of 872 [26%], p=0.59) and 30-day mortality (2 of 194 [1%] vs 14 of 872 [ 2%], p=0.75). A regression analysis showed age (hazard risk, 1.04; 95% confidence interval, 1.02 to 1.06) and coronary artery disease (hazard risk, 1.58; 95% confidence interval, 1.05 to 2.40) were associated with an elevated risk of complications in those undergoing lobectomy, whereas female sex (hazard ratio, 0.63; 95% confidence interval, 0.44 to 0.91) was protective. ACOSOG "high-risk" status was not associated with perioperative morbidity. CONCLUSIONS: There are no important differences in early postsurgical outcomes between lung cancer patients characterized as "high-risk" and "normal-risk" by ACOSOG trial enrollment criteria, despite a significant proportion of "high-risk" patients undergoing lobectomy.
BACKGROUND: The American College of Surgery Oncology Group (ACOSOG) trials z4032 and z4033 prospectively characterized lung cancerpatients as "high-risk" for surgical intervention, and these results have appeared frequently in the literature. We hypothesized that many patients who meet the objective enrollment criteria for these trials ("high-risk") have similar perioperative outcomes as "normal-risk" patients. METHODS: We reviewed a prospective institutional database and classified patients undergoing resection for clinical stage I lung cancer as "high-risk" and "normal-risk" by ACOSOG major criteria. RESULTS: From 2000 to 2010, 1,066 patients underwent resection for clinical stage I lung cancer. Of these, 194 (18%) met ACOSOG major criteria for risk (preoperative forced expiratory volume in 1 second or diffusion capacity of the lung for carbon monoxide≤50% predicted). "High-risk" patients were older (66.4 vs 64.6 years, p=0.02) but similar to controls in sex, prevalence of hypertension, diabetes, and coronary artery disease. "High-risk" patients were less likely than "normal-risk" patients to undergo a lobectomy (117 of 194 [60%] vs 665 of 872 [76%], p<0.001). "High-risk" and control patients experienced similar morbidity (any complication: 55 of 194 [28%] vs 230 of 872 [26%], p=0.59) and 30-day mortality (2 of 194 [1%] vs 14 of 872 [ 2%], p=0.75). A regression analysis showed age (hazard risk, 1.04; 95% confidence interval, 1.02 to 1.06) and coronary artery disease (hazard risk, 1.58; 95% confidence interval, 1.05 to 2.40) were associated with an elevated risk of complications in those undergoing lobectomy, whereas female sex (hazard ratio, 0.63; 95% confidence interval, 0.44 to 0.91) was protective. ACOSOG "high-risk" status was not associated with perioperative morbidity. CONCLUSIONS: There are no important differences in early postsurgical outcomes between lung cancerpatients characterized as "high-risk" and "normal-risk" by ACOSOG trial enrollment criteria, despite a significant proportion of "high-risk" patients undergoing lobectomy.
Authors: D H Harpole; M M DeCamp; J Daley; K Hur; C A Oprian; W G Henderson; S F Khuri Journal: J Thorac Cardiovasc Surg Date: 1999-05 Impact factor: 5.209
Authors: Mark K Ferguson; James J Dignam; Juned Siddique; Wickii T Vigneswaran; Amy D Celauro Journal: Eur J Cardiothorac Surg Date: 2012-02-24 Impact factor: 4.191
Authors: S F Khuri; J Daley; W Henderson; K Hur; J O Gibbs; G Barbour; J Demakis; G Irvin; J F Stremple; F Grover; G McDonald; E Passaro; P J Fabri; J Spencer; K Hammermeister; J B Aust Journal: J Am Coll Surg Date: 1997-10 Impact factor: 6.113
Authors: Philip A Linden; Raphael Bueno; Yolonda L Colson; Michael T Jaklitsch; Jeanne Lukanich; Steven Mentzer; David J Sugarbaker Journal: Chest Date: 2005-06 Impact factor: 9.410
Authors: Benjamin D Kozower; Shubin Sheng; Sean M O'Brien; Michael J Liptay; Christine L Lau; David R Jones; David M Shahian; Cameron D Wright Journal: Ann Thorac Surg Date: 2010-09 Impact factor: 4.330
Authors: Hiran C Fernando; Rodney J Landreneau; Sumithra J Mandrekar; Shauna L Hillman; Francis C Nichols; Bryan Meyers; Thomas A DiPetrillo; Dwight E Heron; David R Jones; Benedict D T Daly; Sandra L Starnes; Angelina Tan; Joe B Putnam Journal: J Thorac Cardiovasc Surg Date: 2011-08-26 Impact factor: 5.209
Authors: DuyKhanh P Ceppa; Andrzej S Kosinski; Mark F Berry; Betty C Tong; David H Harpole; John D Mitchell; Thomas A D'Amico; Mark W Onaitis Journal: Ann Surg Date: 2012-09 Impact factor: 12.969
Authors: Roman O Kowalchuk; Michael R Waters; Sujith Baliga; K Martin Richardson; Kelly M Spencer; James M Larner; Charles R Kersh Journal: Transl Lung Cancer Res Date: 2020-10
Authors: Varun Puri; Traves D Crabtree; Jennifer M Bell; Stephen R Broderick; Daniel Morgensztern; Graham A Colditz; Daniel Kreisel; A Sasha Krupnick; G Alexander Patterson; Bryan F Meyers; Aalok Patel; Clifford G Robinson Journal: J Thorac Oncol Date: 2015-12 Impact factor: 15.609